BiotechTube

ONO-2506

Phase 2/3Terminated
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cerebrovascular Accident

Conditions

Cerebrovascular Accident

Trial Timeline

Nov 1, 2002 → —

NCT ID
NCT00046761

About ONO-2506

ONO-2506 is a phase 2/3 stage product being developed by Ono Pharmaceutical for Cerebrovascular Accident. The current trial status is terminated. This product is registered under clinical trial identifier NCT00046761. Target conditions include Cerebrovascular Accident.

What happened to similar drugs?

5 of 7 similar drugs in Cerebrovascular Accident were approved

Approved (5) Terminated (1) Active (1)
✅Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved
✅ticagrelor + ASA + Placebo+ASAAstraZenecaApproved
✅AtorvastatinPfizerApproved
✅Botulinum toxin type A + PlaceboIpsenApproved
✅Atorvastatin 20mgBrain BiotechApproved
🔄donepezil hclEisaiPhase 3
❌AbciximabEli LillyPhase 3

Hype Score Breakdown

Clinical
15
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00046761Phase 2/3Terminated

Competing Products

14 competing products in Cerebrovascular Accident

See all competitors
ProductCompanyStageHype Score
YM872 (zonampanel)Astellas PharmaPhase 2
35
donepezil hclEisaiPhase 3
40
Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved
43
AbciximabEli LillyPhase 3
32
atomoxetine + StimulantsEli LillyPre-clinical
26
ticagrelor + ASA + Placebo+ASAAstraZenecaApproved
43
ValsartanNovartisPre-clinical
18
AtorvastatinPfizerApproved
43
RivaroxabanBayerPre-clinical
19
Darolutamide (BAY1841788) + EnzalutamideBayerPhase 1
26
Botulinum toxin type A + PlaceboIpsenApproved
40
Atorvastatin 20mgBrain BiotechApproved
40
Autologous bone marrow mononuclear cell transplantationBrain BiotechPhase 1
11
Roflumilast Oral TabletBrain BiotechPhase 2
25